Sexually transmitted infections (STIs) remain public health concerns. Doxycycline post-exposure prophylaxis to prevent STIs is a novel promising intervention, which in a new study caused an ∼65% reduction in incident STIs. However, long-term effects on STI prevalence, microbiomes and antimicrobial resistance among STI pathogens, non-STI pathogens and commensals need to be monitored.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact (WHO, 2021).
Bavinton, B. R. & Grulich, A. E. HIV pre-exposure prophylaxis: scaling up for impact now and in the future. Lancet Public Health 6, E528–E533 (2021).
Molina, J.-M. et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect. Dis. 18, 308–317 (2018).
Luetkemeyer, A. F. et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N. Engl. J. Med. 388, 1296–1306 (2023).
Fiore, M. A., Raisman, J. C., Wong, N. H., Hudson, A. O. & Wadsworth, C. B. Exploration of the Neisseria resistome reveals resistance mechanisms in commensals that may be acquired by N. gonorrhoeae through horizontal gene transfer. Antibiotics 9, 656 (2020).
Kong, F. Y. S., Kenyon, C. & Unemo, M. Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections. J. Antimicrob. Chemother. https://doi.org/10.1093/jac/dkad129 (2023).
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022).
Vanbaelen, T., Manoharan-Basil, S. S. & Kenyon, C. Doxycycline post exposure prophylaxis could induce cross-resistance to other classes of antimicrobials in Neisseria gonorrhoeae: an in-silico analysis. Sex. Transm. Dis. https://doi.org/10.1097/OLQ.0000000000001810 (2023).
Traeger, M. et al. Potential impact and efficiency of doxy-PEP among people with or at risk of HIV. Presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) (2023).
Mortimer, T. D. & Grad, Y. H. A genomic perspective on the near-term impact of doxycycline post-exposure prophylaxis on Neisseria gonorrhoeae antimicrobial resistance. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciad279 (2023).
Work at the WHO Collaborating Centre for Gonorrhoea and Other STIs is supported by grants to M.U. from, for example, the Örebro County Council Research Committee; the Foundation for Medical Research at Örebro University Hospital, Örebro, Sweden; the Global Antibiotic Research and Development Partnership (GARDP); the European Centre for Disease Prevention and Control; and WHO. F.Y.S.K. is supported by a University of Melbourne Faculty C.R. Roper Fellowship.
The authors declare no competing interests.
About this article
Cite this article
Unemo, M., Kong, F.Y.S. Doxycycline-PEP — novel and promising but needs monitoring. Nat Rev Urol 20, 522–523 (2023). https://doi.org/10.1038/s41585-023-00788-1